Drug Discovery Research Partnerships with GSK

GSK’s Discovery Partnerships with Academia (DPAc) is a unique approach to early drug discovery that is designed to provide industrial drug discovery resources and expertise to academic researchers. The concept is simple but powerful: **bring together the insight and creativity of the academic world with the drug discovery expertise of GSK to establish truly integrated collaborations to translate innovative research into clinical benefit for patients.**

You will co-lead a unified team with a DPAc scientist, jointly sharing and publishing data and collectively working towards a medicine.

Your proposal can be in almost any disease area and based on any small molecule or antibody therapeutic. We will initiate target-based collaborations at any time from pre-screening to small molecule or protein optimization.

What you, the academic investigator, bring to the research collaboration:

- **Clear therapeutic drug development hypothesis:** A clear and supportable hypothesis that modulation of target will produce a physiological effect which will be of therapeutic benefit to particular patients.
- **Defined target and/or pathway:** Specific drug target identified and some understanding of type of pharmacology desired.
- **Exclusive enabling expertise:** Your unique know-how, such as reagents, model systems or access to relevant human samples, that is essential to progress the project, and your willingness to commit time and resource(s) to the partnership.
- **Tractability:** Target knowledge that suggests identification of a drug-like molecule is feasible and a path to demonstrating efficacy in the clinic can be defined.

What GSK brings to the research collaboration:

- **Drug discovery expertise & resources:** Assay development and screening capabilities, large and unique compound collections, biopharmaceutical optimization, medicinal chemistry, pharmacokinetics and toxicology
- **Drug development capabilities:** Biopharmaceutical production, chemical synthesis, stability and formulation studies and clinical trial expertise.
- **Funding:** Payments for research in the academic labs to advance the project(s), milestone payments for development success, and royalties for any resultant medicines. If the project terminates, access to key compounds will be provided to you.

Your team will collaborate directly with key researchers from GSK: you provide your critical biological and disease understanding and GSK will contribute a vast range of scientific and drug discovery expertise, experience, and resources.

What GSK is not looking for (but other parts of GSK may be interested!):

- Platforms, vaccines, devices, biomarkers, diagnostics, formulations, basic research
- Diseases of the Developing World (direct link with Tres Cantos Open Lab)
- Other modalities (e.g. nucleoside-based, Cell Therapeutics)
- Completed discovery projects with assets for clinical development
- Repurposing opportunities

**For more information, see:**
DPAc Website: [http://www.dpac.gsk.com/](http://www.dpac.gsk.com/)